Details
June 5 @ 6:30 pm – 8:30 pm CDT
Grand Ballroom CD, Hilton New Orleans Riverside
Supported By: Novo Nordisk A.S.
On-Demand
June 10 @ 12:00 pm – August 10 5:00 pm CDT
Program Description
The Novo Nordisk Industry Symposium at the 2026 Scientific Sessions will be chaired by Professor Donna Ryan and will feature speakers Professor Louis Aronne (USA), Professor Deborah Horn (USA), Professor Jaime Almandoz (USA), Professor Thomas Lutz (Switzerland), and Dr Domenica Rubino (USA).
During the first part of the symposium, the expert faculty will review recent developments in obesity management guidelines, including medical assessment and screening of obesity-related comorbidities, and will explore the latest clinical evidence across approved pharmacological options with focus on GLP-1 receptor agonists. The faculty will also examine the broader health impact of available treatment options beyond weight loss, discussing outcomes related to cardiovascular disease, MASH, obstructive sleep apnoea and knee osteoarthritis.
During the second part of the symposium, the expert panel will focus on the biology of amylin and its role in weight management, including how amylin-based approaches may complement current treatment strategies. The faculty will review emerging clinical data for amylin analogues and will discuss their potential relevance for obesity and obesity-related comorbidities. Furthermore, the faculty will highlight the development path for potential future therapies and will explore how amylin-based therapies may expand future treatment options across weight and type 2 diabetes management.
There will be ample opportunity to ask the faculty questions in two panel discussions after the plenary presentations. We look forward to what promises to be a stimulating and educational symposium.
Speakers
Moderator
Donna Ryan MD, PhD
Professor Emerita
Pennington Biomedical Research Center
New Orleans, LA
Presentation Title: From weight to health outcomes – what is proven?
Presenter
Jaime Almandoz MD, MBA, DABOM, FTOS
Professor of Medicine and Medical Director
UT Southwestern Medical Center
Dallas, TX
Presentation Title: Latest developments in approved pharmacological options – where is the evidence pointing?
Presenter
Deborah Horn DO, MPH, MFOMA
Professor of Internal Medicine
University of Texas McGovern Medical School
Medical Director
UT Center for Obesity Medicine and Metabolic Performance
Houston, TX
Presentation Title: What do emerging clinical data focused on amylin analogues show?
Presenter
Louis Aronne MD, FACP, DABOM
Sanford I. Weill Professor of Metabolic Research
Weill Cornell Medicine
New York City, NY
Additional presentation: What do emerging clinical data focused on amylin analogues show?
Presentation Title: What is the role of amylin biology in weight management?
Presenter
Thomas Lutz Prof. Dr. med. vet., PhD
Professor
Institute of Veterinary Physiology, University of Zurich
Zurich, Switzerland
Presentation Title: From early-phase data to programme design – what is the development path for potential future therapies?
Presenter
Domenica M. Rubino MD
Director
Washington Center for Weight Management & Research
Arlington, VA